Advanced Filters
noise

gliomas Clinical Trials

A listing of gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 321 clinical trials

Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA)

This trial is an open-label, multicenter, phase III clinical study,conducted in patients with newly diagnosed or recurrent malignant high-grade (WHO grades 3~4) glioma, to evaluate the efficacy and safety of a single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder for fluorescence-guided tumor resection and photodynamic diagnosis.

18 - 75 years of age All Phase 3
S SAMI XI, dr

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with Advanced Brain Cancer including Gliomas and Meningiomas . Lifileucel (Amtagvi), the first FDA-approved TIL therapy, has demonstrated significant success in treating unresectable or metastatic melanoma by utilizing …

16 - 90 years of age All Phase 1/2
T Tamika Wong, MPH

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination. Present therapies are inadequate, as evidenced by the low 5-year survival rate for brain cancer patients, with median survival at approximately 12 months. Glioma is the most common form of primary brain cancer, …

18 years of age All Phase 2
U Ugonma Chukwueke, MD

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

18 years of age All Phase 1
O Omar H Butt, M.D., Ph.D.

Window of Opportunity Study of DSP-0390 in Gliomas

This study focuses on determining the pharmacokinetic and pharmacodynamic effect of DSP-0390 in brain and blood from patients with IDH-mutant WHO grade II or III glioma undergoing tumor resection. Tissue will be collected during surgical resection. Blood will be drawn at various time points throughout the 2 weeks of treatment. …

18 years of age All Phase N/A
S Sharon Gardner, MD

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. …

2 - 39 years of age All Phase 2
K Kenneth Cohen, MD, MBA

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals …

12 - 25 years of age All Phase 2

Venous Thromboembolism Prevention in Outpatients With Glioma

This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.

18 years of age All Phase 2
J Junkuan Wang, M.D.

Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

Glioblastoma (GBM) usually grows in a diffuse fashion and infiltrates the surrounding brain. The inability to completely excise the tumor often leads to tumor recurrence within a few months of the initial surgery, which ultimately results in the death of the GBM patient.GBM histologically appears to be a tumor of …

18 years of age All Phase N/A
N Natacha ENTZ WERLE

Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy

Pediatric low-grade glioma (PLGG) is a heterogeneous group of WHO grade I and II brain tumors, associated with a 10-year overall survival of 90%. It is the most common form of primary central nervous system (CNS) tumor arising during childhood, adolescence and young adulthood, accounting for over 30% of CNS …

1 - 25 years of age All Phase 2

Simplify language using AI